Full analysis of Opicapone Capsules: Detailed information at once!

Opicapone is a new type of catechol-O-methyltransferase (COMT) inhibitor, mainly used to treat the motor complications of Parkinson's disease (PD). The drug was developed by the Belgian pharmaceutical company BIAL and approved by European and American drug regulatory agencies as an auxiliary drug for levodopa/dopa decarboxylase inhibitor (levodopa/DDCI) combination therapy. Its trade name is Ongentys.

Opicapone reduces the degradation of levodopa in peripheral tissues by inhibiting the activity of COMT enzyme, thereby increasing the concentration of dopamine in the central nervous system, prolonging the half-life of levodopa, and improving the "on-off" fluctuation phenomenon in patients with Parkinson's disease. This mechanism makes Opicapone important in reducing Parkinson's disease symptoms such as bradykinesia, stiffness, and tremor.

The recommended dose of this drug is 50mg once a day.It is recommended to take it before bed to reduce the incidence of adverse reactions. Because opicapone can prolong the effects of levodopa, some patients may experience side effects such as increased dyskinesia, hallucinations, insomnia, or hypotension. Therefore, doctors usually adjust the dose of levodopa according to the patient's condition to achieve the best therapeutic effect.

Clinical study results of Opicapone show that its efficacy and safety are better than the first generationCOMT inhibitors, such as Entacapone. Due to its long-acting effect, opicapone reduces the number of daily medication doses compared to entacapone and improves patient compliance. In addition, the drug is well tolerated and shows no obvious liver toxicity, making it a breakthrough in the adjuvant treatment of Parkinson's disease.

At present, Opicapone has been launched in many countries around the world and has gradually entered the Chinese market. Patients should consult a neurologist before using this drug to ensure the scientific rationality of the treatment plan, and regularly monitor efficacy and adverse reactions to obtain the best clinical benefit.

Reference materials:https://www.ongentys.com/